肌少症与衰弱:肾脏病主流实践中的挑战
肌少症与衰弱在慢性肾脏病人群中普遍存在,两者在体力维度(握力低、步速慢、肌肉量低)显著重叠,并与多种不良健康结局相关。目前尚无推荐药物治疗,运动训练与营养补充是维持骨骼肌质量与力量的关键干预。本综述全面概述了CKD患者的肌少症与衰弱。
要点
- 肌少症以肌肉量和功能丧失为特征,衰弱是多系统损害导致应激脆弱性增加。
- 两者在握力低、步速慢和肌肉量低等体力方面显著重叠。
- 运动训练和营养补充是维持骨骼肌质量与力量的关键干预。
核心结论
- 肌少症与衰弱在CKD人群中普遍存在且相互重叠,与多种不良健康结局相关。
- 目前无推荐药物治疗,运动训练和营养补充是维持肌肉质量与力量的关键干预。
研究设计与样本
- 综述,旨在全面概述CKD患者的肌少症与衰弱。
主要发现
- 肌少症以肌肉量和功能丧失为特征,衰弱为多系统损害伴应激脆弱性增加。
- 两者在握力低、步速慢和肌肉量低等体力方面显著重叠。
- 两者均与多种不良健康结局相关。
临床怎么用
- 在肾脏病实践中应关注CKD患者的肌少症与衰弱评估。
- 推荐采用运动训练和营养补充以维持骨骼肌质量与力量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Sarcopenia and frailty are prevalent in the chronic kidney disease (CKD) population. Sarcopenia is characterised by the loss of muscle mass and function, while frailty is defined as a multi-system impairment associated with increased vulnerability to stressors. There is substantial overlap between the 2 conditions, particularly with regards to physical aspects: low grip strength, gait speed and low muscle mass. Both sarcopenia and frailty have been associated with a wide range of adverse health outcomes. Although there is no recommended pharmacological treatment as yet, it is widely accepted that exercise training and nutritional supplementation are the key interventions to maintain skeletal muscle mass and strength. This review aims to present a comprehensive overview of sarcopenia and frailty in patients with CKD.
引用
- Wong L, Duque G, McMahon LP, et al. Sarcopenia and Frailty: Challenges in Mainstream Nephrology Practice. Kidney Int Rep. 2021. PMID: 34622096. doi:10.1016/j.ekir.2021.05.039
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。